Adenovirus-mediated transfer of p53 and Fas ligand drastically enhances apoptosis in gliomas

Cancer Gene Therapy

Volumn 7, Issue 5, 2000, Pages 732-738

  Shinoura, Nobusada ^a,b   Yoshida, Yoko ^a   Asai, Akio ^b   Kirino, Takaaki ^b,c   Hamada, Hirofumi ^a,d,e  

^a CANCER CHEMOTHERAPY CENTER   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^d SAPPORO MEDICAL UNIVERSITY   (Japan)

^e CANCER INSTITUTE   (Japan)

Author keywords

Adenovirus; Apoptosis; Fas ligand; Glioma; P53

Indexed keywords

COMPLEMENTARY DNA; FAS LIGAND; PROTEIN P53;

ADENOVIRUS; APOPTOSIS; ARTICLE; BRAIN TUMOR; CONTROLLED STUDY; GENE OVEREXPRESSION; GENE THERAPY; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ADENOVIRIDAE; DNA VIRUSES;

EID: 0034109993     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700160     Document Type: Article

References (40)

1. Harris CC. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst. 1996;88:1442-1455.
2. Roth JA, Nguyen D, Lawrence DD, et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med. 1996;2:985-991.
3. Selvakumaran M, Lin HK, Miyashita T, et al. Immediate early up-regulation of bax expression by p53 but not TGF β1: a paradigm for distinct apoptotic pathways. Oncogene. 1994;9:1791-1798.
4. Marchetti P, Castedo M, Susin SA, et al. Mitochondrial permeability transition is a central coordinating event of apoptosis. J Exp Med. 1996;184:1155-1160.
5. Kluck RM, Bossy-Wetzel E, Green DR, et al. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science. 1997;275:1132-1136.
6. Yang J, Liu X, Bhalla K, et al. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science. 1997;275:1129-1132.
7. Susin SA, Zamzami N, Castedo M, et al. Bcl-2 inhibits the mitochondrial release of an apoptogenic protease. J Exp Med. 1996;184:1331-1341.
8. Owen-Schaub LB, Zhang W, Cusack JC, et al. Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol Cell Biol. 1995;15:3032-3040.
9. Fuchs EJ, McKenna KA, Bedi A. p53-dependent DNA damage-induced apoptosis requires Fas/APO-1-independent activation of CPP32β. Cancer Res. 1997;57:2550-2554.
10. Sager R. Tumor suppressor genes: the puzzle and the promise. Science. 1989;246:1406-1412.
11. Meijerink JP, Mensink EJ, Wang K, et al. Hematopoietic malignancies demonstrate loss-of-function mutations of BAX. Blood. 1998;91:2991-2997.
12. Cascino I, Papoff G, De Maria R, et al. Fas/Apo-1 (CD95) receptor lacking the intracytoplasmic signaling domain protects tumor cells from Fas-mediated apoptosis. J Immunol. 1996;156:13-17.
13. Mandruzzato S, Brasseur S, Andry G, et al. CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma. J Exp Med. 1997;186: 785-793.
14. Kanegae Y, Lee G, Sato Y, et al. Efficient gene activation in mammalian cells by using recombinant adenovirus expressing site-specific Cre recombinase. Nucleic Acids Res. 1995;23:3816-3821.
15. Shinoura N, Yoshida Y, Sadata A, et al. Apoptosis by retrovirus- and adenovirus-mediated gene transfer of Fas ligand to glioma cells: implications for gene therapy. Hum Gene Ther. 1998;9:1983-1993.
16. Niwa H, Yamamura K, Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene. 1991;108:193-199.
17. Yoshida Y, Sadata A, Zhang W, et al. Generation of fiber-mutant recombinant adenoviruses for gene therapy of malignant glioma. Hum Gene Ther. 1998;9:2503-2515.
18. Yoshida Y, Hamada H. Adenovirus-mediated inducible gene expression through tetracycline-controllable transactivator with nuclear localization signal. Biochem Biophys Res Commun. 1997;230:426-430.
19. Telford WG, King LE, Fraker PJ. Evaluation of glucocorticoid-induced DNA fragmentation in mouse thymocytes by flow cytometry. Cell Prolif. 1991;24:447-459.
20. Van Meir EG, Kikuchi T, Tada M, et al. Analysis of the p53 gene and its expression in human glioblastoma cells. Cancer Res. 1994;54:649-652.
21. Weller M, Kleihues P, Dichgans J, et al. CD95 ligand: lethal weapon against malignant glioma? Brain Pathol. 1998;8:285-293.
22. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 1993;74:609-619.
23. Thomas A, El Rouby S, Reed JC, et al. Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance. Oncogene. 1996;12:1055-1062.
24. Shinoura N, Yoshida Y, Asai A, et al. Relative level of expression of Bax and Bcl-XL determines the cellular fate of apoptosis/necrosis induced by the overexpression of Bax. Oncogene. 1999;18:5703-5713.
25. Schott AF, Apel IJ, Nunez G, et al. Bcl-XL protects cancer cells from p53-mediated apoptosis. Oncogene. 1995;11: 1389-1394.
26. Reed JC, Miyashita T, Takayama S, et al. Bcl-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J Cell Biochem. 1996;60:23-32.
27. Ungefroren H, Voss M, Jansen M, et al. Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis. Cancer Res. 1998;58: 1741-1749.
28. Irmler M, Thome M, Hahne M, et al. Inhibition of death receptor signals by cellular FLIP. Nature. 1997;388:190-195.
29. Naumann U, Weller M. Retroviral BAX gene transfer fails to sensitize malignant glioma cells to CD95L-induced apoptosis and cancer chemotherapy. Int J Cancer. 1998;77: 645-648.
30. Tanaka M, Itai T, Adachi M, et al. Downregulation of Fas ligand by shedding. Nat Med. 1998;4:21-22.
31. Trask TW, Aguilar-Cordova E, Goodman JC, et al. A phase I study of adenoviral vector delivery of the HSV-TK gene and the intravenous administration of ganciclovir in adults with malignant tumors of the central nervous system. Proc Am Soc Gene Ther. 1st Annual Meeting; 1998. Abstract.
32. Shinoura N, Ohashi M, Yoshida Y, et al. Construction, propagation, and titer estimation of recombinant adenoviruses carrying proapoptotic genes. Hum Gene Ther. 1998; 9:2683-2689.
33. Jordan J, Galindo MF, Prehn JH, et al. p53 expression induces apoptosis in hippocampal pyramidal neuron cultures. J Neurosci. 1997;17:1397-1405.
34. Tachibana O, Nakazawa H, Lampe J, et al. Expression of Fas/APO-1 during progression of astrocytomas. Cancer Res. 1995;55:5528-5530.
35. Krajewska M, Wang HG, Krajewski S, et al. Immunohistochemical analysis of in vivo patterns of expression of CPP32 (caspase-3), a cell death protease. Cancer Res. 1997;57:1605-1613.
36. Rensing-Ehl A, Malipiero U, Irmler M, et al. Neurons induced to express major histocompatibility complex class I antigen are killed via the perforin and not the Fas (APO-1/CD95) pathway. Eur J Immunol. 1996;26:2271-2274.
37. 2 to M transition: implications for gene therapy. Cancer Res. 1997;57:818-823.
38. Roth W, Fontana A, Trepel M, et al. Immunochemotherapy of malignant glioma: synergistic activity of CD95 ligand and chemotherapeutics. Cancer Immunol Immunother. 1997;44:55-63.
39. Pirollo KF, Hao Z, Rait A, et al. p53-mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy. Oncogene. 1997;14:1735-1746.
40. Sheard MA, Vojtesek B, Janakova L, et al. Up-regulation of Fas (CD95) in human p53 wild-type cancer cells treated with ionizing radiation. Int J Cancer. 1997;73:757-762.